Taro-Dipyridamole/ASA: impurity
Brand(s)
Last updated
Summary
Product
Taro-Dipyridamole/ASA
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot |
|---|---|---|---|---|---|
Taro-Dipyridamole/ASA |
Taro-Dipyridamole/ASA |
DIN 02471051 |
Capsule (immediate and extended release) |
Acetylsalicylic acid 25mg/ |
HAD3873A |
Issue
An impurity is out of trend in the affected batch.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Wholesalers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
|
Taro Pharmaceuticals Canada Inc. 130 East Drive, Brampton, Ontario L6T 1C1 |
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type III
Identification number
RA-74721
Get notified
Receive notifications for new and updated recalls and alerts by category.